Skip to content

CRISPR Therapeutics

US · CRSP #2057 by market cap Listed 2016
52.35 -1.65 -3.06%
Live - 5344 symbols - heartbeat 131s ago · 2026-10-08 08:38
Pre-market 51.51 -1.60%
After-hours 52.65 +0.57%
Overnight 52.09 -0.50%
Market cap
5.06B
P/B
2.90
EPS
-6.47
Reader sentiment Are you bullish or bearish on CRSP?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Morgan Stanley Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $60
    Market Newswire · 2026/6/11
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)
    TipRanks · 2026/6/11
  • Rating change
    A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $76 to $110
    Market Newswire · 2026/5/5
  • Rating change
    Bernstein Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $56
    Market Newswire · 2026/5/13
  • Rating change
    A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $60 to $110
    Market Newswire · 2026/8/5
  • Rating change
    Wells Fargo Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $75
    Market Newswire · 2026/5/6
  • Morgan Stanley Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $60
    Market Newswire · 2026/8/29
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Tenax Therapeutics (TENX) and Belite Bio, Inc. ADR (BLTE)
    TipRanks · 2026/8/31
  • Rating change
    Morgan Stanley Upgrades CRISPR Therapeutics(CRSP.US) to Hold Rating, Raises Target Price to $60
    Market Newswire · 2026/6/11
  • Rating change
    BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $83
    Market Newswire · 2026/7/7
  • Needham Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $82
    Market Newswire · 2026/10/5
  • Rating change
    Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Raises Target Price to $82
    Market Newswire · 2026/5/6
  • Rating change
    Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Raises Target Price to $55
    Market Newswire · 2026/8/6
  • William Blair Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
    Market Newswire · 2026/8/29
  • Rating change
    Piper Sandler Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/7/2
  • Rating change
    Evercore Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Raises Target Price to $76
    Market Newswire · 2026/5/11
  • Evercore Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $76
    Market Newswire · 2026/8/31
  • H.C. Wainwright Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $80
    Market Newswire · 2026/8/31
  • Rating change
    BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82
    Market Newswire · 2026/8/6
  • Rating change
    Goldman Sachs Maintains CRISPR Therapeutics(CRSP.US) With Hold Rating, Maintains Target Price $55
    Market Newswire · 2026/8/10

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:38:48 · For reference only, not investment advice and not tailored to your situation.